Table 2.
Absolute changes in measures of body fat distribution, body composition, and cardiometabolic risk factors during 1 year of hormone therapy in trans women and trans men
| Start of treatment | Mean change (95% CI) | |
|---|---|---|
| Trans women (n = 179) | ||
| Body composition | ||
| Visceral fat (g) | 353 (322, 384) | −2 (−15, 11) |
| VAT/TBF (%) | 1.84 (1.75, 1.92) | −0.31 (−0.35, −0.27) |
| Total body fat (kg) | 19.1 (17.9, 20.2) | 4.0 (3.4, 4.7) |
| Lean body mass (kg) | 57.2 (56.0, 58.4) | −1.7 (−2.1, −1.3) |
| Cardiometabolic parameters | ||
| Total cholesterol (mmol/L) | 4.6 (4.5, 4.8) | −0.6 (−0.7, −0.5) |
| HDL-cholesterol (mmol/L) | 1.4 (1.3, 1.4) | −0.2 (−0.2, −0.1) |
| LDL-cholesterol (mmol/L) | 2.7 (2.6, 2.9) | −0.3 (−0.4, −0.3) |
| Triglycerides (mmol/L) | 1.1 (1.0, 1.2) | −0.2 (−0.3, −0.1) |
| HOMA-IRa | 2.0 (1.8, 2.3) | +0.9 (0.6, 1.3) |
| Trans men (n = 162) | ||
| Body composition | ||
| Visceral fat (g) | 277 (249, 306) | 3 (−10, 16) |
| VAT/TBF (%) | 1.02 (0.95, 1.09) | 0.14 (0.11, 0.18) |
| Total body fat (kg) | 26.0 (24.4, 27.6) | −2.8 (−3.5, −2.2) |
| Total lean body mass (kg) | 46.9 (45.7, 48.2) | +4.7 (4.2, 5.1) |
| Cardiometabolic parameters | ||
| Total cholesterol (mmol/L) | 4.6 (4.4, 4.7) | 0.0 (−0.1, 0.1) |
| HDL-cholesterol (mmol/L) | 1.5 (1.5, 1.6) | −0.2 (−0.3, −0.2) |
| LDL-cholesterol (mmol/L) | 2.6 (2.5, 2.7) | 0.2 (0.1, 0.3) |
| Triglycerides (mmol/L) | 0.9 (0.8, 1.0) | 0.2 (0.1, 0.3) |
| HOMA-IRa | 2.6 (2.3, 2.9) | −0.7 (−1.0, −0.3) |
Data are shown as mean (95% CI).
Abbreviations: HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density lipoprotein; VAT/TBF, visceral adipose tissue/total body fat ratio.
a Eight trans women and 6 trans men were excluded from the specific analysis for having diabetes mellitus.